Ocarnix Oral Solution 500 mg/5 ml
Ocarnix Oral Solution 500 mg/5 ml Uses, Dosage, Side Effects, Food Interaction and all others data.
Ocarnix Oral Solution 500 mg/5 ml is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production in the form of Adenosine Tri phosphate or ATP. Fatty acids are utilized as an energy substrate in all tissues except the brain. In skeletal and cardiac muscle, fatty acids are the main substrate for energy production.
Ocarnix Oral Solution 500 mg/5 ml is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Lack of carnitine can lead to liver, heart, and muscle problems. Carnitine deficiency is defined biochemically as abnormally low plasma concentrations of free carnitine, less than 20 µmol/L at one week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. The "vitamin BT" form actually contains D,L-carnitine, which competitively inhibits levocarnitine and can cause deficiency. Ocarnix Oral Solution 500 mg/5 ml can be used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.
| Trade Name | Ocarnix Oral Solution 500 mg/5 ml |
| Availability | Prescription only |
| Generic | Levocarnitine |
| Levocarnitine Other Names | (R)-Carnitine, Carnitina, Carnitine, L-Carnitine, Levocarnitin, Levocarnitina, Lévocarnitine, Levocarnitine, Levocarnitinum, Vitamin BT |
| Related Drugs | L-Carnitine, Carnitor |
| Weight | 500 mg/5 ml |
| Type | Oral Solution |
| Formula | C7H15NO3 |
| Weight | Average: 161.1989 Monoisotopic: 161.105193351 |
| Protein binding | None |
| Groups | Approved, Investigational |
| Therapeutic Class | Drugs for muscular energy metabolism |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
The supplemental Ocarnix Oral Solution 500 mg/5 ml use is widely established in the management of cardiac ischemia and peripheral arterial disease. It is generally used for cardio protection. It lowers triglyceride levels and increases levels of HDL cholesterol. It is used with benefits in those with primary and secondary carnitine deficiency syndromes. There is also evidence of its use in liver, kidney and immune disorders or in diabetes and Alzheimer's disease. There is little evidence that supplemental Ocarnix Oral Solution 500 mg/5 ml boosts energy, increases athletic performance or inhibits obesity. The indications of Ocarnix Oral Solution 500 mg/5 ml may be summarized as follows:
- Heart Diseases
- Congestive Heart Failure
- Kidney Disease
- Chronic Fatigue Syndrome
- High Cholesterol
- Intermittent Claudication
- Dementia and memory impairment
- Down Syndrome
- Male infertility
- Hyperthyroidism
Ocarnix Oral Solution 500 mg/5 ml is also used to associated treatment for these conditions: Carnitine Deficiency, Congenital carnitine deficiency, Secondary Carnitine deficiency
How Ocarnix Oral Solution 500 mg/5 ml works
Ocarnix Oral Solution 500 mg/5 ml can be synthesised within the body from the amino acids lysine or methionine. Vitamin C (ascorbic acid) is essential to the synthesis of carnitine. Ocarnix Oral Solution 500 mg/5 ml is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. Ocarnix Oral Solution 500 mg/5 ml is handled by several proteins in different pathways including carnitine transporters, carnitine translocases, carnitine acetyltransferases and carnitine palmitoyltransferases.
Dosage
Ocarnix Oral Solution 500 mg/5 ml dosage
Tablet-
- Adults: The recommended oral dosage for adults is 990 mg, two or three times a day using the 330 mg tablets, depending on clinical response.
- Infants and children: The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day. The exact dosage will depend on clinical response.
Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition.Syrup-
- Adults: 10 to 30 ml/day. Dosage should start at 10 ml/day in divided doses, and be increased slowly while assessing tolerance and therapeutic response.
- Infants and children: 50 to 100 mg/kg/day which is equivalent to 0.5 ml/kg/day. Dosage should start at 50 mg/kg/day, and be increased slowly to a maximum of 3 g/day (30 ml/day) while assessing tolerance and therapeutic response. Solution may be consumed alone or dissolved in drink or other liquid food. Doses should be spaced evenly throughout the day (every three or four hours) preferably during or following meals and should be consumed slowly in order to maximize tolerance.
Side Effects
Generally Ocarnix Oral Solution 500 mg/5 ml is well tolerated. However, few side effects including transient nausea and vomiting, abdominal cramps, and diarrhoea may occur
Toxicity
LD50 > 8g/kg (mouse, oral). Adverse effects include hypertension, fever, tachycardia and seizures.
Precaution
The safety and efficacy of oral Ocarnix Oral Solution 500 mg/5 ml has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral Ocarnix Oral Solution 500 mg/5 ml in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine
Interaction
Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments.
Food Interaction
- Take with food. Taking levocarnitine oral solution with meals may reduce gastrointestinal upset such as nausea, vomiting, and cramping.
Volume of Distribution
The steady state volume of distribution (Vss) of an intravenously administered dose, above endogenous baseline levels, was calculated to be 29.0 +/- 7.1L. However this value is predicted to be an underestimate of the true Vss.
Elimination Route
Absolute bioavailability is 15% (tablets or solution). Time to maximum plasma concentration was found to be 3.3 hours.
Half Life
17.4 hours (elimination) following a single intravenous dose.
Clearance
Total body clearance was found to be a mean of 4L/h.
Elimination Route
Following a single intravenous dose, 73.1 +/- 16% of the dose was excreted in the urine during the 0-24 hour interval. Post administration of oral carnitine supplements, in addition to a high carnitine diet, 58-65% of the administered radioactive dose was recovered from urine and feces in 5-11 days.
Pregnancy & Breastfeeding use
Ocarnix Oral Solution 500 mg/5 ml is categorized by the USFDA as Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. Supplemental Ocarnix Oral Solution 500 mg/5 ml should be used by pregnant women only if clearly indicated and only under medical supervision. It is not known whether Ocarnix Oral Solution 500 mg/5 ml is excreted in human milk. Supplemental Ocarnix Oral Solution 500 mg/5 ml is not advised for nursing mothers. Those with seizure disorders should only use Ocarnix Oral Solution 500 mg/5 ml under medical advisement and supervision.
Contraindication
There is no known disease or syndrome in which Ocarnix Oral Solution 500 mg/5 ml administration is contraindicated. It is contraindicated in patients with hypersensitivity to any of its components.
Acute Overdose
There have been no reports of toxicity from levocarnitine overdosage. Ocarnix Oral Solution 500 mg/5 ml is easily removed from plasma by dialysis. The intravenous LD50 of levocarnitine in rats is 5.4 g/kg and the oral LD50 of levocarnitine in mice is 19.2 g/kg. Large doses of levocarnitine may cause diarrhea.
Storage Condition
Tablet: Store in a cool & dry place, protected from light & moisture.
Solution: Store in a cool & dry place, protected from light.
Innovators Monograph
You find simplified version here Ocarnix Oral Solution 500 mg/5 ml
Ocarnix Oral Solution 500 mg/5 ml contains Levocarnitine see full prescribing information from innovator Ocarnix Oral Solution 500 mg/5 ml Monograph, Ocarnix Oral Solution 500 mg/5 ml MSDS, Ocarnix Oral Solution 500 mg/5 ml FDA label
FAQ
What is Ocarnix Oral Solution 500 mg/5 ml used for?
Ocarnix Oral Solution 500 mg/5 ml is used to prevent and treat a lack of carnitine. It is used to prevent and treat this condition in patients with kidney disease on dialysis. It is given to people whose body cannot properly use carnitine from their diet.
How safe is Ocarnix Oral Solution 500 mg/5 ml?
In one review of Ocarnix Oral Solution 500 mg/5 ml safety, doses of approximately 2 grams per day appeared to be safe for long-term use.
How does Ocarnix Oral Solution 500 mg/5 ml work?
Ocarnix Oral Solution 500 mg/5 ml is a naturally occurring substance that the cells of mammals need to produce energy. It is used to treat carnitine deficiency. Ocarnix Oral Solution 500 mg/5 ml is a small protein that binds to and helps transport fatty acids into the mitochondria, the site of energy production within cells.
What are the common side effects of Ocarnix Oral Solution 500 mg/5 ml?
The common side effects of Ocarnix Oral Solution 500 mg/5 ml are upset stomach, nausea, vomiting, diarrhea, headache, muscle pain/weakness, swelling of hands/lower legs/feet, tingling skin, or body odor ("fishy" smell) may occur. If any of these effects persist or worsen, contact your doctor or pharmacist promptly.
Is Ocarnix Oral Solution 500 mg/5 ml safe during pregnancy?
Use is not recommended unless clearly needed. Stopping treatment in a pregnant woman with primary systemic carnitine deficiency may carry serious consequences; the risk of stopping treatment may outweigh the theoretical risks to the fetus of continuing.
Is Ocarnix Oral Solution 500 mg/5 ml safe during breastfeeding?
Taking Ocarnix Oral Solution 500 mg/5 ml is possibly safe in breast-feeding women when taken by mouth in the amounts recommended. Small amounts of Ocarnix Oral Solution 500 mg/5 ml have been given to infants in breast milk and formula with no reported side effects.
Can I drink alcohol with Ocarnix Oral Solution 500 mg/5 ml?
You had better stay away from alcohol in any form while you are on this Ocarnix Oral Solution 500 mg/5 ml and for three days afterward. Read labels carefully and avoid even small amounts of alcohol, as found, for instance, in cough syrups.
When should I take Ocarnix Oral Solution 500 mg/5 ml?
Take Ocarnix Oral Solution 500 mg/5 ml with or just after meals.
How often should I take Ocarnix Oral Solution 500 mg/5 ml?
Ocarnix Oral Solution 500 mg/5 ml should be taken at evenly spaced intervals every 3 or 4 hours.
How long does Ocarnix Oral Solution 500 mg/5 ml take to work?
Ocarnix Oral Solution 500 mg/5 ml levels increase rapidly after i.v. administration (500 mg) to healthy volunteers declining to baseline after 12 h; Ocarnix Oral Solution 500 mg/5 ml levels increase more slowly, reach a peak in 30–60 min, and decline to baseline within 24 h.
Should I take Ocarnix Oral Solution 500 mg/5 ml on an empty stomach?
Ocarnix Oral Solution 500 mg/5 ml supplements are therefore likely to be much better absorbed on an empty stomach.
What is the half life of Ocarnix Oral Solution 500 mg/5 ml?
Using plasma concentrations uncorrected for endogenous Ocarnix Oral Solution 500 mg/5 ml, the mean distribution half life was 0.585 hours and the mean apparent terminal elimination half life was 17.4 hours.
How long can I take Ocarnix Oral Solution 500 mg/5 ml?
Ocarnix Oral Solution 500 mg/5 ml is likely safe when taken for up to 12 months.
Is it safe to take Ocarnix Oral Solution 500 mg/5 ml everyday?
Doses of 2 grams or less per day seem to be well tolerated and safe for most people. Tentative evidence suggests Ocarnix Oral Solution 500 mg/5 ml supplements might increase your risk of atherosclerosis.
Who should not take Ocarnix Oral Solution 500 mg/5 ml?
Do not take Ocarnix Oral Solution 500 mg/5 ml if you are allergic to it. Seek immediate medical attention if you notice any symptoms such as skin rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, breathing difficulty, etc.
What happens if I miss a dose?
Oral forms: If you missed a dose of Ocarnix Oral Solution 500 mg/5 ml, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not take two doses together to make up for a missed dose.
Injection: Since Ocarnix Oral Solution 500 mg/5 ml is given in the hospital setting by a qualified healthcare professional, the likelihood of missing a dose is very low.
What happens if I overdose on Ocarnix Oral Solution 500 mg/5 ml?
Oral forms: Never take more than the prescribed dose of Ocarnix Oral Solution 500 mg/5 ml. If you suspect that you might have taken an overdose of this medicine, seek immediate medical help.
Injection: Since Ocarnix Oral Solution 500 mg/5 ml is administered by a healthcare professional, the chances of overdose are very less. However, your doctor will take measures if an overdose is suspected
Can Ocarnix Oral Solution 500 mg/5 ml affect my kidneys?
Ocarnix Oral Solution 500 mg/5 ml is excreted from the kidneys. If you have kidney problems this medicine may accumulate in your kidneys and leads to serious side effects. Your doctor may adjust the dose of this medicine based on your clinical condition. Ocarnix Oral Solution 500 mg/5 ml is not recommended for use if you have severe kidney problems.
Does Ocarnix Oral Solution 500 mg/5 ml cause fatty liver?
Firstly, reduced levels of Ocarnix Oral Solution 500 mg/5 ml may lower fatty acid oxidation and be a contributing factor in the accumulation of liver fat.
Does Ocarnix Oral Solution 500 mg/5 ml cause heart disease?
Ocarnix Oral Solution 500 mg/5 ml can absolutely cause heart disease - but only if you have the gut microbes needed to break it down.
Can Ocarnix Oral Solution 500 mg/5 ml raise blood pressure?
Ocarnix Oral Solution 500 mg/5 ml shown strong correlations between insulin resistance and increased blood pressure.
